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TheCommunity Pharmacy of theDepartment of Ambulatory Care andCommunityMedicine (PolicliniqueMe´dicaleUniversitaire,
PMU), University of Lausanne, developed and implemented an interdisciplinary medication adherence program. The program
aims to support and reinforce medication adherence through a multifactorial and interdisciplinary intervention. Motivational
interviewing is combined with medication adherence electronic monitors (MEMS, Aardex MWV) and a report to patient,
physician, nurse, and other pharmacists. This program has become a routine activity and was extended for use with all chronic
diseases. From 2004 to 2014, there were 819 patient inclusions, and 268 patients were in follow-up in 2014. This paper aims to
present the organization and program’s context, statistical data, published research, and future perspectives.
1. Introduction
A widely known challenge in chronic healthcare is the
percentage of patients who do not follow their medication
regimen, from poor adherence to nonadherence [1]. When
patients take their medications as prescribed, they are con-
sidered to be adherent. Adherence has two components that
are complementary to each other: persistence and implemen-
tation. Persistence describes the length of time between the
first and last doses. Implementation describes the initiation
of treatment (when the patient takes his or her first dose);
the implementation of the dosing regimen (if the patient
follows the actual prescribed dosing regimen); and, finally,
the discontinuation of treatment [2].TheWorldHealthOrga-
nization (WHO) estimates that only 50% of chronic patients
correctly take their medication, depending on the patient’s
disease, medication, and demographic characteristics [1]. For
example, 62% of the world’s HIV-positive population is more
than 90% adherent to medication [3]. Nonadherence has
obvious consequences not only for a patient’s health (e.g.,
nonefficacy of the treatment or disease progression) but also
for healthcare costs (e.g., the number of medical visits, rate of
hospitalization, extended stays in hospitals, or multiplication
of diagnostic tests) [4, 5]. According to a 2012 report by
the IMS Institute for Healthcare Informatics, 8% of total
healthcare costs worldwide are spent unnecessarily, due to the
suboptimal use of medicines. Out of that 8%, approximately
57% is due to nonadherence, which represents $270 billion
dollars [6]. In Switzerland, costs related to nonadherence are
estimated to be 30 billion CHF, which is 50% of annual health
care costs [7].
Addressing the problem of nonadherence would evi-
dently help alleviate the burden of added costs to healthcare.
To do so, healthcare systems need to change by developing
interdisciplinary medication adherence intervention pro-
grams to ensure better adherence to medication, especially
to chronic therapies [1]. Worldwide, there are some activities
within healthcare systems that support or monitor medica-
tion adherence as part of more comprehensive programs,
such as medication review (Australia, Spain, Denmark, and
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Finland); identification of drug-related problems (Sweden);
andmedication checks (Denmark) [8].The pharmacist deliv-
ers themajority of these programs, but there are some that are
multiprofessional, involving physicians or nurses. There are
also initiatives that do not involve pharmacists. For example,
the Cincinnati Children’s Hospital Medical Center (USA)
developed and implemented an empirically informed com-
prehensive model of pediatric adherence promotion in the
management of pediatric chronic conditions [9]. Some gov-
ernments start to reimburse pharmacists for related services
to support medication adherence, such as in Switzerland,
England, or Belgium [8, 10]. For example, in England, they
introduced the third round of pharmaceutical services (or the
New Medicine Service, NMS) in 2011 to promote the health
and well-being of patients who start a new medication [11].
In 2004, based on previous experience with other chronic
diseases, the Community Pharmacy of the Department of
Ambulatory Care and Community Medicine (Policlinique
Me´dicale Universitaire, PMU), University of Lausanne, in
collaboration with the Infectious Diseases Service of the Lau-
sanne University Hospital (CHUV, Lausanne, Switzerland),
developed and implemented an interdisciplinary antiretrovi-
ral therapy (ART) adherence program forHIV patients. Since
then, this program has become a routine activity and was
extended for use with all chronic diseases. The program aims
to support and reinforce medication adherence through a
multifactorial and interdisciplinary intervention. According
to the National Institute for Health and Care Excellence’s
(NICE) 2009 Guidelines, it is important to involve patients in
decisions about prescribedmedicines and adherence support
[12]. This is why the pharmacist, who is part of the developed
intervention program at the PMU, is interested in empower-
ing the patient’s autonomy with treatment as much as possi-
ble. The adherence program’s main goal is to increase med-
ication adherence to achieve therapeutic goals. However, it
is important to set achievable, realistic intermediate subgoals
to initiate and maintain patient-empowered long-term treat-
ment behavior. Motivational interviewing is combined with
medication adherence electronic monitors (MEMS, Aardex
MWV, Switzerland) and report that provides feedback to the
patient, physician, nurse, and other pharmacists. Electronic
measure of medication adherence allows professionals to
provide feedback to the patient on the dosing history and
thereby enhance patient medication adherence [13].
This paper aims to describe the organization and pro-
gram’s context, statistical data, published research on medi-
cation adherence interventions, and future prospects for the
medication adherence program at the PMU.
2. Methodology
2.1. Background Information. The physician, pharmacist, or
nurse invites the patient to take part in the program, but
in practice, the physician is often the best person to invite
the patient to participate in the program because of the
established patient-provider relationship. The first interview
between the patient and pharmacist happens on the same day
or within a few days after the patient agrees to participate
in the program. The following interviews are arranged with
the patient and called follow-up interviews, which take place
30–45 minutes before a medical visit and last for 15–30
minutes. The medication adherence interview is conducted
when medicines are given and happens in an interview room
to ensure confidentiality. At the beginning of each interview,
the pharmacist validates the medical prescriptions to ensure
treatment is prescribed in a safe, effective, adequate, and eco-
nomic way and according to evidence-basedmedicine. At the
end of each follow-up interview and with the patient’s con-
sent, a report is sent to the physician.The patient is informed
that the pharmacist, physician, and nurse exchange informa-
tion to support medication adherence. Any decision to stop
the program is made mutually by the physician and pharma-
cist in collaboration with the patient. In this case, a discon-
tinuation visit takes place with the pharmacist (see Figure 1).
The frequency of interviews depends first on the patient’s
needs and second on his or her availability (on average, once
a month to once a trimester). For example, an HIV patient
starting a new treatment attends a medical visit at 2 and 4
weeks and at 2, 3, 4, and 6 months if no problem of toxicity
appears.The pharmacist organizes the medication adherence
interview according to these medical visits. The pharmacist
also plans extrainterviews in betweenmedical visits, in case of
difficulties to adherence that could potentially lead to clinical
consequences. Special attention is given at the beginning of
follow-up.
Medication adherence interviews are scheduled in the
pharmacy’s electronic agenda to keep track of all patients. A
pharmacy technician, specialized in medication adherence,
checks the agenda at least once a day and validates the
daily list of scheduled patients. If the next interview date is
not yet scheduled with a patient, the technician enters an
electronic reminder to contact the patient 10 days before a
shortage of medicines occurs. If a patient does not come to
an interview, the technician contacts the patient to arrange
another appointment. In the case of 3 unsuccessful calls and
before a shortage of medicine, the pharmacist contacts the
physician to decide on a mutual action. The physician invites
the patient to return for a medical appointment and to visit
the adherence clinic.
All information is collected electronically at the phar-
macy, which uses 2 software programs for the medication
adherence program: medAmigo [14] or SISPha [15].
2.1.1. Inclusion of Patients. When a patient agrees to take part
in the adherence program, the physician calls the pharmacist,
who completes a document for the “medication adherence
program request.” This document gathers details on the
patient (name, sex, birth date, address, phone number,
spoken languages, availability of a translator if needed, and
half-day preferences for interviews); details on the physician
(contact information and knowledge of the adherence pro-
gram); and clinical data (reasons for the request, diagnosis
and comorbidities, complete medicine treatment, and deter-
mination of medicines for monitoring).
Themain reasons to include a patient in this program are
the following:
(i) failure to achieve therapeutic goals;
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Figure 1: Medication adherence program—organizational process. Note. EMs = electronic monitors of medication adherence.
(ii) adherence difficulties exposed by the patient and/or
discussed with the physician, pharmacist, or nurse;
(iii) difficult psychosocioeconomic conditions;
(iv) complexity of the current treatment (increasing dose
or dosage, introduction of a new medicine);
(v) comorbidities known to affect medication adherence
(e.g., depression, anxiety, illicit drug use, and alcohol);
(vi) history of nonpersistence to treatment;
(vii) frailty known to have an impact onmedication adher-
ence (e.g., teenagers, especially during their transition
from pediatric to adult medicine, pregnancy, and
postpartum in HIV+ women).
2.1.2. First Interview with the Pharmacist. The interview
consists of 4 parts. During the first part of the interview,
the pharmacist describes the nature and direction of the
program, which is completely new to most patients; sets the
framework (time over which interviews take place, length
of interviews); and assesses the patient’s readiness to start
or keep taking the treatment. While the pharmacist is the
one who guides the interviews (semidirective intervention),
the patient is invited to actively participate in the interviews,
according to the principle of patient-centered care. The
interviews can be attended by the patient alone or with a
significant other. A 1-page leaflet with written information is
provided to the patient. This document also attests that the
electronic monitors (EMs) are delivered on a loan basis to
the patient and must be returned at the end of the program.
Otherwise, the pharmacy would claim the cost of the EM
by sending an invoice to the patient. This document is then
signed and dated by the patient and pharmacist.
During the second part of the interview, the pharmacist
gets to know the patient’s personal and psychosocial condi-
tions (e.g., if the patient lives alone or is surrounded by a circle
of social support); therapeutic history (current and previous
treatments, doses and dosages, former nonadherent and
nonpersistent behaviors, and reasons); experienced barriers
and facilitators to medication intake; and previous adherence
support, if any (e.g., pillbox, directly observed therapy, home
nurse, significant-other support). Having this information
then starts the intervention.
During the interview’s third part, the pharmacist presents
the EMs and verifies that the patient can adopt them without
any major difficulties (e.g., manual dexterity or visual issues
or neurocognitive troubles). The patient is informed that the
EM records the day and the hour of each opening and that
this information is made available to the patient at any time
through the LCD screen on top of the monitor. To prevent
a mix of monitors and their containers, each corresponding
EM and its container are marked with the same color. The
patient is asked to bring back EMs at each medication
adherence interview, even if there is still some medicine
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remaining, as the pharmacist always delivers more medicine
than necessary to anticipate any appointment changes.
During the interview’s fourth part, the pharmacist
presents the monitored treatment and provides medical
pamphlets. Afterward, the patient and pharmacist schedule
medication intake by combining the pharmaceutical recom-
mendationwith the patient’s ownpreferences, and they define
individual, appropriate use for the patient. In case of drug
continuation, the pharmacist considers the patient’s current
and previous organization, as well as capturing former and
actual barriers and facilitators to support the patient in
finding sound, individual, and appropriate use.
Finally, the pharmacist invites the patient to ask ques-
tions, summarizes the interview, and eventually sets a realistic
short-term goal to meet first for the next interview and fixes
the next appointment.
2.1.3. Follow-Up Interviews. Follow-up interviews focus on
the patient’s adherence and medicine-related issues (e.g.,
regimen, side effects). The pharmacist prepares the interview
and at least reviews 2 to 3 previous reports, including the
inclusion document if he or she does not know the patient.
The pharmacy technician uploads EMs data and counts
returned pills. The differences between electronic adherence
and pill count exceeding 20% are explored afterward. At the
start of the interview, the pharmacist may remind the patient
about the nature and direction of the program and provide
a summary of the last interview. Before presenting the latest
data on the EMs, the pharmacist validates the electronic data
and assesses self-reported adherence by asking the patient the
following questions:
(i) Within which time interval do you take your
medicine after opening the EMs? The answer is then
categorized (≤1 hour, >1 hour, and variable).
(ii) Are EMs consistently used for each dose or did
you organize pocket dosing or experience nonmon-
itored periods (e.g., during a hospitalization where
treatment was delivered from the hospital supply by
the nursing staff)? The pharmacist notes dates and
reasons for each deviation of EM use with the greatest
possible accuracy.
(iii) Do you think you have missed taking some pills since
the last interview? If yes, then the patient describes
when, how much, and in which circumstances and
reasons (unintentional/intentional). This informa-
tion allows the pharmacist to identify whether self-
reported adherence is close or not to electronic
adherence and guide the presentation of EM results
by accounting for the patient’s attitude.
After validating the use of the EMs, the pharmacist shows,
describes, and discusses the EM results with the patient. The
results are displayed using patient-friendly graphs (calendar
and chronology, see Figure 2). Showing the report often
generates spontaneous patient comments and steers the
discussion. The pharmacist congratulates the patient on the
days with correct medication intake and encourages small
progress. If the EMdepicts missed doses, the pharmacist pays
attention to themost recentlymissed ones and then goes back
in time and asks the patient to describe what happened that
was usual or unusual on the same day. The patient exposes
perceived medication intake barriers and facilitators.
The intervention’s framework is based on the sociocogni-
tive theory, especially the Information-Motivation-Behavioral
Skills model (IMB model, see Figure 3) [16]. This compre-
hensive, cognitive, motivational, and behavioral intervention
progresses at the patient’s rhythm, using motivational inter-
viewing skills by paying particular attention to the patient’s
language of change, thanks to empathy and active and
reflective listening. During the interview, nonadherent
patients are invited to describe their attitude and barriers to
medication intake. At the same time, the pharmacist helps
them in exploring facilitators to medication intake, and this
eventually results in the adjustment of their own behavior in
a timely and autonomous way.
The cardinal points of the intervention are as follows:
(i) Information. The pharmacist assesses the patient’s
knowledge (adherence, treatment, and disease);
informs him/her according to individual, evolving
needs; and/or refers the patient to the physician.
(ii) Motivation in Medication Intake. The pharmacist
assesses the patient’smotivation; patient’s own clinical
and quality of life expectations; and emotions linked
to the treatment (e.g., anxiety, fear, disinterest, and
denial) to check that emotional needs are balanced,
such as by expectations and/or social or practical
support that the patient receives.
(iii) Behavioral Skills. The pharmacist explores the levels
of integration of medication intake in the patient’s
daily routine; self-efficacy; capacity to self-manage
treatment and side effects; and the patient’s strategies
to prevent missed doses (e.g., management at home
and if out of the home, during weekends, holidays,
or in case of an unfamiliar schedule, reminders, and
storage).
In case the physician foresees a change in treatment, the
pharmacist explores the patient’s opinion about this change
and discusses previous change experiences, if any, and the
patient’s readiness for this upcoming change.
Moderators of Fisher’s model—such as psychological
clinical or subclinical deficit, unstable living situation, poor
access to medical care, and substance abuse—are considered.
According to the identified variable affecting adherence, the
pharmacist, physician, or nurse takes the lead in supporting
the patient. For example, in case psychosocial components
affect adherence, the patient could be referred to a psychol-
ogist or psychosocial worker. In case treatment complexity
is the main trigger of nonadherence, the pharmacist and the
physician identify ways to simplify treatment. Finally, the
pharmacist helps the patient in setting realistic goals until
the next interview and summarizes the interview. Then, the
pharmacist fixes the next appointment and invites the patient
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Figure 2: Example: results of an electronic monitor—calendar and graph (from medAmigo [14]).
to call him/her in case of intercurrent medication intake
problems.
The pharmacist finalizes themedication adherence report
and sends it to the physician at a maximum of 3 days after
the interview or gives the report directly to the patient if
the medical visit happens on the same day. The three main
goals of this electronic report are to ensure (1) continuity
of care between the pharmacist, physician, and nurse and a
multidirectional flow of information; (2) continuity of care
at the pharmacy between interviews, with the possibility
to easily notice changes in patient adherence (maintenance,
increase, and decrease over time); and (3) quality manage-
ment and activity’s traceability. The report presents the EMs’
adherence results and the pharmacist’s comments according
to 3 sections:
(i) Objective description of the patient’s adherence since
the last interview and validation of EMs use (overall
adherence and timing, description of days without
intake—isolated, clustered, change over time—with a
focus on special life events, which affect adherence).
(ii) Description of medication adherence facilitators and
barriers encountered by the patient, including medi-
cation side effects and symptoms.
(iii) Summary of the intervention based on the IMBmodel
and adherence subgoal(s) for the next interview.
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Information
(i) Dose and dosage, correct 
use, and adequate adherence 
(ii) Side effects, interactions
(iii) Heuristics and implicit
theories about medication
adherence
Motivation
(i) Personal motivation: 
attitudes/beliefs about 
consequences of an adherent 
and anonadherent behavior and 
perspectives
(ii) Social motivation: perceptions 
of adherence support provided 
by the entourage
Behavioral skills
Objective and perceived abilities (self-efficacy) 
(i) For acquiring, self-cueing, and self-administering
of medications 
(ii) For incorporating regime into society, ecology of 
daily life
(iii) For minimizing side effects
(iv) For updating medication adherence data
(v) For acquiring social support and instrumental 
support for adherence 
(vi) For self-reinforcement of adherence over time
Adherence behavior
(i) Proper dosing
compared with the 
prescription
(ii) Optimal adherence
(iii) Maintenance of 
adherence over time
Health outcomes
(i) Clinical outcomes
(ii) Objective health
status
(iii) Subjective health
status
(iv) Quality of life
Moderating factors
(ii) Unstable living situation
(iii) Poor access to medical care
(iv) Substance abuse or addiction 
(i) Psychological health (anxiety, depression, etc.)
Figure 3: Fisher’s model—Information-Motivation-Behavioral Skills model of adherence to antiretroviral treatment (adapted from Fisher et
al. [16]). Note.HAART = highly active antiretroviral therapy.
After each medical visit, the patient returns to the pharmacy
to fill the EMs with the prescribed pills until the next
appointment.
2.1.4. Phases and Closing the Medication Adherence Program.
Themedication adherence program is divided into 3 phases:
(1) Initiation Phase (Generally Months 0 to 6). Problems
are clearly identified and a search for solutions takes
place. During this phase, the patient is followed as
often as possible by the same pharmacist (in collab-
oration with a substitute pharmacist).
(2) Consolidation Phase (Generally Months 6 to 12). The
patient enters this phase if he or she achieved 4 con-
ditions: (1) he or she achieved or came significantly
closer to his or her therapeutic goals, (2) medication
adherence improved and has been adequate for a
minimum of 4 months, (3) identified barriers to
adherence are either resolved or balanced by facilita-
tors, and (4) at least 3 adherence interviews were con-
ducted. During this phase, the patient consolidates
the newly learned adherence behavior, and it is no
longer necessary to be seen by the same pharmacist
every time, as in the previous phase.
(3) Maintenance Phase (Generally Months 12 and Later).
Adherence has been adequate for the last 12 months,
barriers encountered are solved or self-managed by
the patient, and a major clinical improvement in
therapeutic goals is achieved. Patients are invited to
stop the program after the pharmacist, physician, and
nurse agree on it. However, some patients express
their wish to continue the program. This wish can
be because the EMs structure the patient’s daily
medication intake, and the electronic feedback given
during medication interviews increases the patient’s
feeling of security. In this case, uploads of EMs data
are scheduled 3 to 4 times a year, and interviews are
short, based on electronic feedback. If new adherence
issues emerge, the patient is invited to enter a new
initial phase.
At the end of the program or if the patient decides to quit
prematurely, a closing visit is scheduled. The reason for
closing is detailed in the report, especially whether treatment
is pursued or not. The pharmacist informs the patient of the
possibility of relapse and ways to decrease its risk, including
letting the patient know that the adherence program remains
available at any time.
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2.1.5. Handling EMs. Tomaximize efficiency, pharmacy tech-
nicians are in charge of logistics and technical work linked to
EMmanagement.They activate and program EMs and check
their functional use before the first delivery and also upload
EM data before each interview. The pharmacists prepare and
fill in EMs at each prescription refill and document this
activity in a dedicated form. Additionally, the pharmacist
verifies the medicine stability in EMs.
2.2. Training the Team. The medication adherence program
is ISO certified. All procedures arewritten andmade available
to the team at any time.
2.2.1. Pharmacists’ Training. First, the new pharmacists
receive basic training. They attend a 10-hour class organized
into 5modules: (1) introduction tomedication adherence, (2)
theoretical frameworks ofmedication adherence, (3)medica-
tion adherence intervention programs, (4) structure of medi-
cation adherence interviews, and (5) case studies. After these
modules, pharmacists in training observe a minimum of 3
medication-adherence interviews with a trained pharmacist.
Second, pharmacists are trained in motivational inter-
viewing during four 4-hour sessions [17]. They include prac-
tical exercises, discussions, illustrations, and role play. Then,
participants have the opportunity to benefit from a filmed
interview with a simulated patient and receive feedback from
a professional.
Third, pharmacists in training deliver 3 to 8 medication-
adherence interviews, depending on the pharmacist’s expe-
rience and skills, under the supervision of a senior trainer
(pharmacist) who attends the interview, gives feedback after
each interview, and validates each medication adherence
report.
To maintain a high and standardized quality level for the
medication adherence program, one interview per pharma-
cist is recorded every 18 months, and a debriefing with a
trainer is conducted. Every 6 to 8 weeks, a 1-hour adherence
internal meeting is organized for educational purposes and
discussing complex case studies.
2.2.2. Pharmacy Technicians’ Advising. Pharmacy techni-
cians are advised on the spot by trained technicians and phar-
macists. While there is no formal training for the new tech-
nicians, they participate in the adherence internal meetings.
3. Results and Discussion
3.1. Context and Published Research. The Community Phar-
macy of the Department of Ambulatory Care and Commu-
nity Medicine is linked to the Research Unit of Community
Pharmacy, School of Pharmaceutical Sciences, University of
Geneva-University of Lausanne. The Community Pharmacy
practice helps and gives ideas to the research team and
in parallel, this academic setting promotes research and
development [18].
Progressive for the time, the medication adherence pro-
gram started in 1995. The Community Pharmacy intro-
duced EMs without showing medication adherence data to
patients and physicians. When results were shown for the
first time to patients, pharmacists and physicians noticed
patients’ positive reactions [19]. In 2004, a new interdis-
ciplinary collaboration with the infectious diseases service
of the CHUV boosted the program with the inclusion of
HIV patients, so the program became a structured routine
activity [20–24]. Interdisciplinary collaboration leads to a
safer and coordinated healthcare system for patients and their
families with more involvement in decision-making. It also
facilitates access to healthcare interventions [25].Thenumber
of trained pharmacists increased, and pharmacy technicians
were integrated in the program. We did a hand search
of all published literatures on the medication adherence
program at the PMU. Details can be found in Supplementary
Appendix 1 (see Supplementary Appendix 1 in the Supple-
mentaryMaterial available online at http://dx.doi.org/10.1155/
2015/103546).
The intervention follows the Behavior Change Technique
Taxonomy by Michie et al. that was developed to provide
an extensive consensually agreed structured taxonomy for
behavior change techniques used in interventions [26] (see
Table 1).
3.2. Results Describing the Adherence Program Activity. From
2004 to 2014, 819 patients were included and pharmacists
delivered 10’911 interviews for different chronic diseases from
2008 to 2014 (see Figures 4 and 5). All patients accepted
using EMs, and EMs are not imposed on patients; alternative
solutions are available, for example, weekly pill organizers.
In 2014, 268 patients were followed up, out of whom 187
were HIV patients; 28 multiple sclerosis patients; 9 oncology
patients; and 44 patients for other chronic diseases (e.g.,
hypertension, type 2 diabetes, and chronic dialysis).
On average, patients have 2 EMs over their entire follow-
up period [IQR: 1–3; min-max 1–8]. The duration of the
follow-up is long with a median of 333 days for HIV patients
[IQR: 138–799; min-max 11–3317]. Medication adherence
is a dynamic process that needs long-term follow-up [1].
Indeed, such a longitudinal measure of patients’ medication
adherence allows for capturing adherence’s evolution over
time. For example, pharmacists in this program detect the
precursory signs of a possible deterioration of medication
adherence (e.g., increase in timing fluctuation of medication
intake) and work with patients during the interview on
preventing further deterioration. Two consequent interviews
are generally separated by a median of 33 days [IQR: 15–77].
Themedian is very close forHIV,multiple sclerosis, and other
chronic diseases but is higher for oncology with a median of
49 days [IQR: 30–95] (see Table 2).
To run this program, the pharmacy needs 1 full-time
pharmacist, 1 full-time pharmacy technician, and 1 alternate
pharmacist for busy days. On average, interviews last for
approximately 10 minutes [IQR: 5–15]. Pharmacy technicians
take 20 minutes [IQR: 15–25] to prepare medicines for the
first interviews and 13 minutes [IQR: 9–20] for follow-up
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Table 1: Patient-level intervention according to Michie’s et al. taxonomy [26].
Michie’s et al.
taxonomy Intervention
Goals and planning Set realistic goals and adjust them to build up skills, use the problem solving technique, and raise awareness ondiscrepancy between current behavior and goals as a motor of change
Feedback and
monitoring
Electronic monitoring, empathic reinforcement, alliance through LCD display of electronic pill monitor, and
ensuring continuity of care through medication adherence report
Social support Reinforce positive practical and/or emotional support, invite significant others to attend interview, and offer thepossibility to bring adherence report back home to discuss it with significant others
Shaping knowledge Assess patient’s cognitive and behavioral knowledge and needs in regard to long-term adherence, short-termand long-term side effects, fill in gaps with adequate vocabulary, and reevaluate needs over time
Natural consequences
Evaluate consequences, which are relevant to the patient (e.g., health, quality of life, and social, emotional,
affective, financial, and professional consequences) and use hypotheses as a motor of potential changes (e.g.,
what would happen if you would take your medication on a regular basis?)
Comparison of
behavior Ask the permission for telling what other patients did in a similar situation
Associations Associate drug intake with relevant individual daily actions, behaviors, cues, and reminders
Repetition and
substitution Plan short but repeated interviews over time, adjusted to patients’ needs
Comparison of
outcomes Compare change in clinical outcomes and in adherence and set future goals
Reward and threat Congratulate patient on achievements as small as they are; if necessary, evoke risks cautiously with patientagreement
Regulation Detangle possible triangulation between patient and healthcare providers, listen to and regulate emotions, and,if possible, wait and see if patient is not ready to change behavior (preparation phase)
Antecedents Evaluate adherence with past treatments as indicator
Identity Reinforce patient positive behaviour, respect patient’s rhythm and possibilities, and keep contact with patient(e.g., schedule a new interview in case of a missed appointment)
Scheduled
consequences Identify changes in clinical outcomes
Self-belief Explore patient’s past success, empower patient, and support patient in building self-confidence, self-efficacy,and motivation with treatment
Covert learning —
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Figure 4: Inclusion in the medication adherence program and stop from 2004 to 2014. Note. Patients who reentered the program after a gap
of more than 1 year were considered to be new inclusions.
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Figure 5: Number of medication adherence interviews delivered by pharmacists.
Table 2: Time intervals in-between interviews and time per patient
visit to the medication adherence program (visits 𝑛 = 7171).
Median IQR
Time intervals in-between interviews [days]
HIV 34 [15–78]
Multiple sclerosis (MP) 28 [20–42]
Oncology 49 [30–95]
Other chronic conditions 35 [19–64.5]
Total 33 [15–77]
Time needed for inclusion interviews [minutes]
Interview 10 [5–15]
Report 25 [17–36.5]
EMs handling 20 [15–25]
Total 60 [45–76.5]
Time needed for follow-up interviews [minutes]
Interview 10 [5–15]
Report 12 [7–20]
EMs handling 13 [9–20]
Total 38 [27–50]
Note. IQR = interquartile range.
interviews, and pharmacists take 25 minutes [IQR: 17–36.5]
to complete the report for the first interviews and 12 minutes
[IQR: 7–20] for follow-up interviews (see Table 2).
3.3.What about the Cost ofThis Program? In Switzerland, the
healthcare insurance system is based on cost sharing, as the
insured person pays part of the treatment’s cost.This payment
is made in the form of annual deductibles (called the fran-
chise).The amount of themonthly insurance premium is then
adjusted, depending on the franchise (the higher limit of the
franchise is 2500 CHF per year).When the franchise exceeds,
which is often the case with chronic conditions, patients pay
10% of the care costs until they reach a maximum quota of
700 CHF per year. After this quota, all care is reimbursed to
the patient, including pharmaceutical services, for example, a
medication adherence support fee (20.80 CHF per week) and
a polymedication check fee (48.60 CHF every 6months) [27].
3.4. ProgramProspects. Our first prospect for thismedication
adherence program is to extend the research to diseases other
than HIV. Studies currently in progress concern chronic dial-
ysis, hypertension, type 2 diabetes,multiple sclerosis, and oral
oncology. Cost-effectiveness analyses are also in progress.
The second prospect is to implement this program in
other community pharmacies in the French-speaking part
of Switzerland. The program is also in the process of being
implemented for HIV patients at the Hospital of Neuchaˆtel
(Switzerland) in collaboration with local physicians, nurses,
and community pharmacies.
4. Conclusion
This paper thoroughly describes the experience of a well-
established adherence program in Lausanne, Switzerland.
It is an intervention that includes motivational interviews,
electronic pill monitors, and reports, and it has interdisci-
plinary collaboration between all healthcare professionals.
It is used with chronic patients experiencing or at risk of
experiencing medication adherence issues. The fact that it is
patient-centered makes it possible for the patients to develop
autonomy.The program bridges research and practice, and it
encourages the implementation of such a program elsewhere
in the world. More articles should describe similar successful
intervention programs to promote experience exchanges,
comparisons, and replications in different settings.
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